Palvella Therapeutics (PVLA) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Palvella Therapeutics (PVLA) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.23 of bullish evidence against -0.37 bearish.

Palvella Therapeutics last closed at $132.16, -0.23% on the session.

Against the IVW growth benchmark the position is -1.15% over the forecast window.

The read is built from 12 underlying insights — 2 bullish and 10 bearish.

Agreement across those insights is 83%.

3 graded predictions for PVLA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Palvella Therapeutics in the 18th percentile on return on equity, where 100 is best.

Palvella Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $1.91B.

StockMap tracks Palvella Therapeutics as the 88th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Palvella Therapeutics ranks 238th of 344 in the group, against a group median of -0.21.